A chronic eosinophilic leukemia patient presenting with blurred vision

References (5)

1. Valent P Pathogenesis, classification and therapy of eosinophilia and eosinophil disorders. Blood Reviews 2009;23:157-65.
2. Bain B, Gilliland DG, Vardiman JW, Horny HP Chronic eosinophilic leukaemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classifi- cation of tumours of haematopoietic and lymphoid tissues, vol. 2. Geneva (Switzerland) and Albany (NY, USA): WHO Press; 2008;51-3.
3. Bain B, Gilliland DG, Horny HP Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnor- malities of PDGFRA, PDGFRB, orFGFR1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 2. Geneva (Switzerland) and Albany (NY, USA): WHO Press; 2008;68-73.
4. Sheikh J, Weller FW. Advances in diagnosis and treat- ment of eosinophilia. Current Opinion in Hematology 2009;16:3-8.
5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14.